Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,473.47
(
0.37%
)
US TECH 100
28,963.60
(
0.91%
)
Dow Jones
50,579.70
(
0.58%
)
Brent Oil
96.40
(
-4.71%
)
Bitcoin
76,658.06
(
-0.79%
)
News Focus
News Focus
Post# of 257628
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123010
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: oc631 post# 106748

Wednesday, 10/20/2010 2:16:57 PM

Wednesday, October 20, 2010 2:16:57 PM

Post# of 257628

Why breed speculation in the market and attention as to what GILD's HCV program is lacking?

The investment community is well aware of GILD’s pipeline deficiencies. Now that Genentech is no longer independent, GILD is probably the most closely scrutinized biotech company in the entire industry.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today